What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2021-02-25 compared with 2020-03-05 · 60 added, 48 removed, 82 unchanged (57% of the section changed)

7 unchanged sentences

In June 2008, Mr.

Patel formed Synageva BioPharma Corp., or Synageva, a biotechnology company focused on rare diseases, where he served as President and Chief Executive Officer and was a member of its board of directors until Synageva’s sale to Alexion Pharmaceuticals, Inc., or Alexion, in June 2015.

Prior to Synageva, Mr.

7 unchanged sentences

, has served as our Lead Independent Director and on our Board of Directors since October 2015.

Baker is Co-Managing Member of Baker Bros.

Baker is a Managing Member of Baker Bros.

Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies, or Baker Bros.

Baker and his brother, Julian Baker, started their fund management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family.

In 2000, they founded Baker Bros.

Baker currently serves on the boards of directors of Alexion, Seattle Genetics, Inc., and Kodiak Sciences Inc., or Kodiak Sciences, and previously served on the board of directors of Genomic Health, Inc., or Genomic Health, and Synageva.

Baker founded Baker Bros.

Advisors., together with his brother Julian Baker, in 2000.

Baker currently serves on the boards of directors of Alexion, Seagen, Inc., and Kodiak Sciences Inc., or Kodiak Sciences, and previously served on the boards of directors of Genomic Health, Inc., or Genomic Health, Seattle Genetics, Inc., and Synageva.

Baker holds a B.S.

10 unchanged sentences

in Genetics from the University of Rochester.

Bradley Cole has served as a member of our Board of Directors since July 2020.

He served as Executive Advisor of Exact Sciences Corporation, or Exact Sciences, from April 2020 to September 2020, and from November 2019 until April 2020 he served as its GM, Precision Oncology.

Prior to that, Mr.

Cole served as Chief Financial Officer of Genomic Health, Inc., or Genomic Health, a molecular diagnostics company, from July 2014 to November 2019 and from July 2004 to January 2011, and as Chief Operating Officer of Genomic Health from January 2009 until March 2018, which was acquired by Exact Sciences.

Cole served as Secretary of Genomic Health from February 2005 until July 2012.

From December 1997 to May 2004, he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group.

From January 2001 until May 2004 he served as Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation.

Previously, Mr.

Cole served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company.

Cole currently serves on the board of directors of Castle Biosciences, a skin cancer diagnostics company.

He also serves on the Genomic Life, Inc., or Genomic Life, board of directors, a private company, and as Vice Chairman of the Board of Trustees of Biola University.

Cole holds a B.S.

in Business from Biola University and an M.B.A.

from San Jose State University.

has served on our Board of Directors since March 2019.

3 unchanged sentences

Levy served as Executive Vice President and Chief Drug Development Officer at lncyte Corporation, a biopharmaceutical company, from January 2009 until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009.

Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., ArTara Therapeutics, Inc.

Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc.

(f/k/a ArTara Therapeutics, Inc.), Constellation Pharmaceuticals Inc.

and Kodiak Sciences, and previously served on the board of directors of Aquinox Pharmaceuticals, Inc.

1 unchanged sentence

in Biology from Brown University and an M.D.

from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.

from the University of Pennsylvania School of Medicine,

and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.

Malley has served as a member of our Board of Directors since December 2016.

13 unchanged sentences

From May 1997 to September 2016, Ms.

McCain held various roles at Genzyme, including as General Counsel following Genzyme’s acquisition by Sanofi in 2011.

McCain holds a J.D.

2 unchanged sentences

Popovits has served as a member of our Board of Directors since February 2018.

Popovits served as the Chief Executive Officer of Genomic Health from 2009-2020, and served as the chairman of the board of directors of Genomic Health from 2012-2020.

Popovits also serves on the board of directors of MyoKardia, Inc., and previously served on the board of directors of ZS Pharma Inc.

Popovits holds a B.A in Business from Michigan State University.

Popovits served as Genomic Health’s Chairman of the Board from 2012 through 2019, and Chief Executive Officer and President from 2009 through 2019.

She was President and Chief Operating Officer upon joining the company in 2002.

Prior to leading Genomic Health, Ms.

Popovits served as Senior Vice President, Marketing and Sales at Genentech, Inc.

During her 15 years at Genentech, Ms.

Popovits led the successful commercialization of 14 new therapies, including Herceptin.

Popovits currently serves on the board of directors of 10x Genomics, Inc.

and previously served on the boards of directors of MyoKardia, Inc.

and ZS Pharma, Inc.

She also serves on the boards of directors of the Coalition for 21 st Century Medicine, the Personalized Medicine Coalition, Talis Inc., Wamberg Genomic Advisors, and Genomic Life.

She also serves as an Executive Advisor to Blackstone Life Sciences and is an Advisor to the Healthcare Businesswomen’s Association (HBA).

Popovits holds a Bachelor of Arts degree in Business from Michigan State University.

Quart, Pharm.D.

8 unchanged sentences

Patel has served as our Chief Executive Officer and Chairman of our Board of Directors since our formation in July 2015.

See “—Directors of the Registrant”

Patel’s biography.”

Thomas Beetham has served as our Executive Vice President, Corporate Development and Operations since November 2019 and serves as our Chief Legal Officer, a role he has held since our formation in July 2015, and also serves as our Secretary.

See “—Directors of the Registrant” for Mr.

Patel’s biography.

Thomas Beetham has served as our Executive Vice President, Corporate Development and Operations, Chief Legal Officer and Secretary since November 2019.

Previously, Mr.

Beetham served as our Executive Vice President, Corporate Development, Chief Legal Officer and Secretary since December 2015, and previously as Senior Vice President in the same roles since our formation in July 2015.

Prior to that, Mr.

1 unchanged sentence

Prior to joining Synageva, from 2011 to 2013, Mr.

Beetham was the General Legal Counsel for New England Biolabs, Inc., or Biolabs, where he was responsible for all legal matters and was a member of Biolabs’

global business development team.

Beetham was the General Legal Counsel for New England Biolabs, Inc., or Biolabs, where he was responsible for all legal matters and was a member of Biolabs’ global business development team.

Before Biolabs, Mr.

Beetham held various roles at Genzyme, most recently as the lead corporate attorney responsible for Genzyme’s hematology/oncology and multiple sclerosis products, and before that was a business and transactional attorney with the law firm of Palmer & Dodge, LLP.

Beetham holds a J.D.

from Boston College Law School, an M.B.A.

from Boston College’s Carroll School of Management, and a B.A.

from the University of Rochester.

Chris Heberlig has served as our Chief Financial Officer since our formation in July 2015 and also serves as our Treasurer.

Prior to serving as our Chief Financial Officer, Mr.

Heberlig held various roles at Synageva from 2008 to 2015, most recently serving as Senior Vice President of Finance and Business Operations.

Earlier in his career, Mr.

Heberlig held senior financial management positions at Panacos Pharmaceuticals, Inc., or Panacos, and EPIX Pharmaceuticals, Inc., or EPIX, both biotechnology companies.

Prior to Panacos and EPIX, he worked at PricewaterhouseCoopers LLP, a national audit, tax, and advisory service firm.

Heberlig holds an M.B.A.

from Boston University and a B.A.

Lawrence University.

Heberlig is also a Certified Public Accountant.

Mark Ragosa has served as our Vice President and Interim Chief Financial Officer since December 2020, at which point he also assumed the role of principal financial officer.

As our Interim Chief Financial Officer, Mr.

Ragosa oversees our Finance and Investor Relations organizations.

Prior to that, Mr.

Ragosa served as our Vice President, Investor Relations and Finance since May 2020 having served as our Vice President, Investor Relations since May 2018.

In these roles Mr.

Ragosa oversaw the development and execution of our strategic investor-relations plan aligned with our long-term goals and contributed to our capital raise strategy.

Prior to that, Mr.

Ragosa served as Director, Investor Relations from February 2018 to May 2018 and Associate Director from September 2016 to February 2018 at Ironwood Pharmaceuticals Inc, a biotechnology company, or Ironwood, where he managed relationships with investors and analysts and served as an external spokesperson.

Prior to joining Ironwood, Mr.

Ragosa served as a Vice President within the equities division at Goldman Sachs Group, Inc.

from March 2012 to June 2016 where, among other things, he facilitated capital raises for private and public companies and conducted financial analyses.

Prior to that Mr.

Ragosa held roles within the equities divisions at Morgan Stanley and Bank of America Securities.

Ragosa received his bachelor’s degree in History and Government at Bowdoin College and is a Chartered Financial Analyst.

Paolini, M.D., Ph.D.

6 unchanged sentences

from Duke University School of Medicine, a B.A.

from Tulane University, and completed his internship, residency and fellowship in Internal Medicine and Cardiology at Brigham and Women’s Hospital, Boston.

Qasim Rizvi MBChB., MBA., has served as our Senior Vice President of Operations & Chief Commercial Officer since November 2019, prior to that Dr.

Rizvi served as our Chief Commercial Officer since July 2019 and was our Senior Vice President, Operations since August 2018.

Prior to that, Dr.

Rizvi served in roles of increasing responsibility at Genentech, Inc., or Genentech, a member of the Roche Group, or Roche, having joined the company in June 2006.

From October 2017 to August 2018, Dr.

Rizvi served as Genentech’s Vice President and U.S.

Franchise Head of Tecentriq, with commercial responsibilities for Genentech’s Cancer Immunotherapy portfolio.

From September 2016 to October 2017, Dr.

Rizvi served as Vice President –

Franchise Head Hematology;

Global Product Strategy at

Roche, where he led the global hematology franchise.

From October 2014 to September 2016, Dr.

Rizvi served as Life Cycle Leader at Genentech, where he was responsible for bringing Roche’s Hemophilia product from Phase 1b to the global commercialization.

Prior to joining Genentech/Roche, Dr.

Rizvi was at Novo Nordisk and Eli Lilly, where he served in numerous roles in sales, marketing, business development and new product planning.

Rizvi received his medical degree from the University of Dundee School of Medicine.

He completed his residency in general surgery and holds an M.B.A in Marketing and Corporate Strategy from the University of Michigan’s Stephen M.

Ross School of Business.

from Tulane University, and completed his internship, residency and fellowship in Internal Medicine and Cardiology at Brigham and Women’s Hospital, Boston.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings